Navidea, Cardinal Health deal

Navidea will sell its Lymphoseek tilmanocept imaging agent to Cardinal Health for oncology indications for $80 million up front and up to $230 million in annual earn-out and sales milestone payments. Prior to the deal, Cardinal was the U.S. commercialization partner for the product...